NasdaqGS - Nasdaq Real Time Price
USD
Insulet Corporation (PODD)
143.38
+0.33
(+0.23%)
At close: August 26 at 4:00:00 PM EDT
145.00
+1.62
(+1.13%)
After hours: August 26 at 7:35:26 PM EDT
Trade Insulet on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for PODD
Chart does not reflect overnight price.
What's happening with PODD?
Powered by Yahoo ScoutInsulet (PODD) faces challenges despite a strong Q2 performance, leading to a 56% declineover the past year. Analysts express mixed sentiments, with a consensus rating of Moderate Buybut lowered growth expectations for 2026, as concerns about Type 2 diabetes retention and competition weigh on investor confidence.
Powered by Yahoo Scout
- Previous Close
143.05 - Open
141.27 - Bid 132.58 x 200
- Ask 154.34 x 200
- Day's Range
141.23 - 144.63 - 52 Week Range
126.40 - 354.88 - Volume
1,423,967 - Avg. Volume
1,607,469 - Market Cap (intraday)
9.944B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
26.85 - EPS (TTM)
5.34 - Earnings Date (est.) Nov 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
171.91
Recent News
View More
Performance Overview
Trailing total returns as of 8/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
PODD
49.56%
S&P 500 (^GSPC)
12.13%
1-Year Return
PODD
56.79%
S&P 500 (^GSPC)
18.71%
3-Year Return
PODD
21.65%
S&P 500 (^GSPC)
74.22%
5-Year Return
PODD
51.25%
S&P 500 (^GSPC)
71.72%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/25/2026
-
Market Cap
9.92B
-
Enterprise Value
10.33B
-
Trailing P/E
26.84
-
Forward P/E
23.64
-
PEG Ratio (5yr expected)
1.44
-
Price/Sales (ttm)
3.35
-
Price/Book (mrq)
6.98
-
Enterprise Value/Revenue
3.38
-
Enterprise Value/EBITDA
15.83
Financial Highlights
Profitability and Income Statement
-
Profit Margin
12.29%
-
Return on Assets (ttm)
9.71%
-
Return on Equity (ttm)
26.02%
-
Revenue (ttm)
3.05B
-
Net Income Avi to Common (ttm)
375.3M
-
Diluted EPS (ttm)
5.34
Balance Sheet and Cash Flow
-
Total Cash (mrq)
534.9M
-
Total Debt/Equity (mrq)
66.68%
-
Levered Free Cash Flow (ttm)
236.9M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap
undefined
-
Industry
-
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Lowering target price to $157.00
INSULET CORP has an Investment Rating of BUY; a target price of $157.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $163.00
INSULET CORP has an Investment Rating of BUY; a target price of $163.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Lowering target price to $159.00
INSULET CORP has an Investment Rating of BUY; a target price of $159.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Insulet Earnings: Solid Quarterly Results Give Way to Impending Deceleration in Second Half
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
RatingPrice Target
